Keyword: Navitor Pharmaceuticals
CAR-T player Cellectis poached a Novartis exec; GSK recruited a CFO to spearhead cost-cutting; Thomas Hughes leaves Zafgen to lead Navitor; and more.
Hughes helmed Zafgen through a turbulent time in which it abandoned its lead candidate after patients died in a phase 3 study.
The financing gives Laura Deming, who started work on the fund before turning 18, $22 million to invest in companies working on age-related diseases.
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health in return for an equity stake and a source of future milestones and royalties.